A novel anti-angiogenic agent, TRC105 (also known as c-SN6j), developed in the laboratory of Ben K. Seon, PhD, Department of Immunology, Roswell Park Cancer Institute (RPCI) has the potential to be an effective agent for the treatment of solid tumors. The United States Food and Drug Administration (FDA) approved TRC105 as an Investigational New Drug (IND). A phase I clinical trial, supported by government grants and sponsored by TRACO Pharmaceuticals will be performed at RPCI and three other medical centers.

FDA-Approved Novel Anti-Cancer Agent Developed At Roswell Park For Clinical Trials


Post a Comment

Google Analytics Alternative